Patents by Inventor Karen C. Sitney

Karen C. Sitney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY
    Publication number: 20130316448
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Application
    Filed: August 2, 2013
    Publication date: November 28, 2013
    Applicant: AMGEN INC.
    Inventors: Thomas C. Boone, Kenneth D. Wild, Karen C. Sitney, Ho-Sung Min, Bruce Kimmel
  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 8513396
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 20, 2013
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth D. Wild, Karen C. Sitney, Ho-Sung Min, Bruce Kimmel
  • METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ANEMIA
    Publication number: 20120322730
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Application
    Filed: August 17, 2012
    Publication date: December 20, 2012
    Inventors: Joan C. EGRIE, Steven G. Elliot, Jeffrey K. Browne, Karen C. Sitney
  • Methods and compositions for the prevention and treatment of anemia
    Patent number: 8268588
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: September 18, 2012
    Assignee: Amgen Inc.
    Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
  • PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY
    Publication number: 20120129771
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Application
    Filed: February 1, 2012
    Publication date: May 24, 2012
    Applicant: AMGEN INC.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Therapeutic peptides
    Patent number: 8143380
    Abstract: The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: March 27, 2012
    Assignee: Amgen Inc.
    Inventors: Kenneth W. Walker, Olaf B. Kinstler, Karen C. Sitney
  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 8124724
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: February 28, 2012
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Methods and Compositions for the Prevention and Treatment of Anemia
    Publication number: 20110256586
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Application
    Filed: June 24, 2011
    Publication date: October 20, 2011
    Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
  • Peptides and Related Compounds Having Thrombopoietic Activity
    Publication number: 20110229472
    Abstract: The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.
    Type: Application
    Filed: December 22, 2010
    Publication date: September 22, 2011
    Applicant: Amgen Inc.
    Inventors: Hosung Min, Karen C. Sitney, Cynthia Hartley
  • Methods and compositions for the prevention and treatment of anemia
    Patent number: 7977311
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 12, 2011
    Assignee: Amgen Inc.
    Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
  • Methods and compositions for the prevention and treatment of anemia
    Patent number: 7973009
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 5, 2011
    Assignee: Amgen Inc.
    Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
  • Peptides and related molecules that modulate nerve growth factor activity
    Publication number: 20100240582
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Application
    Filed: January 24, 2008
    Publication date: September 23, 2010
    Inventors: Thomas C. Boone, Kenneth D. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Modified Fc molecules
    Patent number: 7750127
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: July 6, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7750128
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: July 6, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7662931
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7655764
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 2, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7655765
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 2, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Patent number: 7645861
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 12, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Publication number: 20090286964
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Application
    Filed: August 1, 2008
    Publication date: November 19, 2009
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Modified Fc molecules
    Publication number: 20090281286
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Application
    Filed: August 1, 2008
    Publication date: November 12, 2009
    Inventors: Colin Gregg, Fei Xiong, Karen C. Sitney